The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Self-citationIntegrase inhibitors to treat HIV/Aids
Pommier, Y., Johnson, A. A., & Marchand, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1660 · Cited by 688
Grinsztejn, B., Nguyen, B.-Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., & Isaacs, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60597-2 · Cited by 574
Markowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Hare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
Min, S., Song, I., Borland, J., Chen, S., Lou, Y., Fujiwara, T., & Piscitelli, S. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-09 · Cited by 244
Self-citationLennox, J. L., DeJesus, E., Berger, D. S., Lazzarin, A., Pollard, R. B., Ramalho Madruga, J. V., Zhao, J., Wan, H., Gilbert, C. L., Teppler, H., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181da1287 · Cited by 228
Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-11 · Cited by 226
Min, S., Sloan, L., DeJesus, E., Hawkins, T., McCurdy, L., Song, I., Stroder, R., Chen, S., Underwood, M., Fujiwara, T., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834a1dd9 · Cited by 222
Self-citation
Cited by
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
Self-citationRaffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 379
Self-citationHIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Smith, S. J., Zhao, X. Z., Burke, T. R., & Hughes, S. H. (2018) · Retrovirology · doi:10.1186/s12977-018-0420-7 · Cited by 114
Metadata
- Authors
- van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., & Min, S.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 12
- Issue
- 2
- Pages
- 111-118
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2098185748
- Cited by
- 301
- References
- 14
- FWCI
- 20.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. https://app.cochat.ai/papers/10.1016/s1473-3099(11)70290-0
- The paper
- van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., & Min, S. (2012). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(11)70290-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
